Literature DB >> 16263420

Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes.

Evan C Howe1, Marcin Wlodarski, Edward J Ball, Lisa Rybicki, Jaroslaw P Maciejewski.   

Abstract

OBJECTIVE: Recent reports have shown that killer immunoglobulin-like receptors (KIR) and KIR ligand (KIR-L) genotype play a role in the pathophysiology of autoimmune disorders. Certain KIR/KIR-L combinations might convey a predisposition to immune-mediated bone marrow failure. Examining the genotypic makeup of human leukocyte antigen (HLA) class I (KIR-L) and KIR in patients with hematologic disorders could offer clues to immunogenetic risk factors for these diseases. The objective of this study is to establish the frequency of specific KIR genes and KIR-L alleles in aplastic anemia (AA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplasia (MDS), and large granular lymphocyte leukemia (LGL), as compared with healthy control patients.
METHODS: KIR genotyping was performed on DNA from 113 patients with AA, PNH, MDS, and LGL using sequence specific primer amplification. Results of genotypic KIR analysis were examined with HLA typing. Comparisons in frequency of KIR-L groups, KIR genotype profiles, and KIR/KIR-L mismatch were performed to determine whether specific KIR genes and KIR-L are overrepresented in bone marrow failure states.
RESULTS: No difference in frequency of KIR-L groups was found relative to the healthy controls. AA and PNH showed decreased frequency of KIR-2DS1 and KIR-2DS5 genes: KIR-2DS1 35% vs 21% (p = 0.15) for AA and 19% for PNH (p = 0.13); KIR-2DS5 31% vs 14% (p = 0.08) for AA and 12% (p = 0.06) for PNH. These differences were even greater when compared to a larger group of control individuals from a study with similar genetic background.
CONCLUSIONS: The reduced frequency of these KIR in AA and PNH may indicate an immunogenetic relationship between these diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263420     DOI: 10.1016/j.exphem.2005.07.005

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

Review 1.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

Review 2.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young; Rodrigo T Calado; Phillip Scheinberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

Review 3.  Immune pathogenesis of paroxysmal nocturnal hemoglobinuria.

Authors:  Ramon Tiu; Jaroslaw Maciejewski
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 4.  Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.

Authors:  Lucio Luzzatto; Giacomo Gianfaldoni
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

5.  Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.

Authors:  P K Epling-Burnette; Lubomir Sokol; Xianhong Chen; Fanqi Bai; Junmin Zhou; Michelle A Blaskovich; JianXiang Zou; Jeffrey S Painter; Todd D Edwards; Lynn Moscinski; Jeffrey A Yoder; Julie Y Djeu; Said Sebti; Thomas P Loughran; Sheng Wei
Journal:  Blood       Date:  2008-09-12       Impact factor: 22.113

Review 6.  Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options.

Authors:  Giulia Calabretto; Antonella Teramo; Gregorio Barilà; Cristina Vicenzetto; Vanessa Rebecca Gasparini; Gianpietro Semenzato; Renato Zambello
Journal:  Cells       Date:  2021-10-19       Impact factor: 6.600

Review 7.  Persistent Large Granular Lymphocyte Clonal Expansions: "The Root of Many Evils"-And of Some Goodness.

Authors:  Carlos Bravo-Pérez; Salvador Carrillo-Tornel; Esmeralda García-Torralba; Andrés Jerez
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

8.  Immunological derangement in hypocellular myelodysplastic syndromes.

Authors:  B Serio; Am Risitano; V Giudice; N Montuori; C Selleri
Journal:  Transl Med UniSa       Date:  2014-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.